Using the amyloid-β precursor protein (APP)/PS1 mouse model of Alzheimer’s disease, it was confirmed that chrysin reduced cognitive impairment in AD by decreasing the levels of amyloid-β and phosphorylated tau, along with the dual-inhibitory activity against β-site-amyloid precursor protein cleaving enzyme 1 (β-secretase 1, β-site APP cleaving enzyme 1, BACE1) and glycogen synthase kinase 3β (GSK3β) [23]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.